Allogene: If MRD Holds, This Becomes A Completely Different Company

Allogene Therapeutics presents an asymmetric setup, with the market undervaluing its focused pivot and emerging clinical validation. ALPHA3 is the central value driver, aiming to shift CAR-T into MRD-guided first-line consolidation with strong early MRD clearance and an unusually clean outpatient profile. ALLO maintains a $423.6M cash balance, disciplined cost controls, and a runway into 2029, supporting key clinical catalysts without near-term dilution risk. Valuation reflects low probability of success; credible efficacy from ALPHA3 or ALLO-329 could drive significant multiple expansion as revenue-based frameworks become relevant. Thesis Allogene Therapeutics (ALLO ) seems to be setting up as a classic asymmetric biotech play going into 2H26. I think the market is still anchoring the stock to cash plus some option value, despite this